Press Releases

DUBLIN, Aug. 10, 2017 /PRNewswire/ --

• Delivered second quarter 2017 GAAP ("reported") net sales of $1.2 billion
• CHC Americas segment reported nets sales of $605 million compared to $630 million last year, lower by 4%; Adjusted net sales grew 3%, excluding $42 million from the U.S. VMS business in the prior year
• Second quarter reported net loss of $70 million and reported diluted loss per share ("EPS") of $0.49
• Delivered strong second quarter adjusted net income of $175 million and adjusted diluted EPS of $1.22
• CHC International segment profit improvement plan continued to yield positive results with second quarter reported operating margin of 1.0% and adjusted operating margin of 14.6%
• RX segment reported second quarter operating margin of 28.8%; the segment's extended topical strategy yielded strong adjusted operating margin of 46.5%, an improvement of 370 bps compared to the prior year
• First half 2017 cash flow from operations was $285 million, or a robust $390 million excluding a tax payment of $74 million and restructuring payments of $31 million
• Used enhanced balance sheet flexibility to repurchase approximately 812,000 shares for approximately $58 million in the second quarter
• Reached an agreement to divest Israel Active Pharmaceutical Ingredient (API) business for $110 million in cash

Outlook:

• The Company now expects calendar year 2017 reported diluted EPS to be in the range of $0.84 to $1.09. Given continued positive execution across all of our business segments, the Company raised its calendar year 2017 adjusted diluted EPS guidance to be in the range of $4.45 to $4.70. This adjusted diluted EPS guidance range includes the removal of approximately $0.05 second half expected contribution due to the sale of the API business.

Perrigo Company plc (NYSE; TASE: PRGO) today announced results for the second quarter ended July 1, 2017.

Additional GAAP reported results: Reported net sales were lower in the Consumer Healthcare Americas ("CHCA") and Consumer Healthcare International ("CHCI") segments by 4% and 9%, respectively, due primarily to actions taken last year to sell non-profitable businesses. CHCA reported operating margin was 17.2%.

Perrigo CEO John T. Hendrickson commented, "We are very pleased with the performance across all segments this quarter, and these results demonstrate the Company's continued positive execution in our businesses. Two key governing principles I have discussed over the past year for Perrigo are operational excellence and being action orientated. Operational excellence was once again visible in our results this quarter. Our CHCA segment delivered solid adjusted net sales growth of approximately 3% in both the second quarter and over the last twelve months. For the sixth consecutive quarter, adjusted operating margin in this business has remained above 20%. Our CHCI segment delivered an impressive 4% net sales growth in the quarter, on a constant currency basis and excluding the exited distribution businesses. RX adjusted operating margin was a solid 47%, 370 bps higher than the prior year. Finally, our durable business model and efficient supply chain delivered strong cash flow through the first half of the year.

The second principle, being action oriented, was evidenced by the following actions this quarter: 1) execution of our cost optimization program, which is on track to deliver annual cost savings of greater than $130 million by the middle of 2018; 2) advancement of our debt pay down strategy by concluding the $1.4 billion tender offer during the quarter, which provides greater optionality and flexibility to utilize our improved balance sheet as demonstrated by the $58 million of share repurchases; and 3) continued refinement of our portfolio through the announced sale of the Israel API business and the Russia CHC International business. We continue to capitalize on our unique business model and are focused on providing Quality Affordable Healthcare Products^® to customers, patients and families around the globe."

Refer to Tables I - VI at the end of this press release for a reconciliation of non-GAAP adjustments to the current year and prior year periods and additional non-GAAP information. The Company's reported results are included in the attached Condensed Consolidated Statements of Operations, Balance Sheets and Statements of Cash Flows.

Second Quarter Results

 

Reported net sales for the second quarter of 2017 were $1.2 billion, which included discontinued products of $10 million and new product sales of $38 million.  Adjusted net sales grew 2% compared to the prior year excluding: 1) net sales from the VMS business of $42 million, which was sold in the third quarter of 2016, 2) net sales from the European distribution businesses of $39 million, which the Company exited in 2016, 3) lower year-over-year net sales of $26 million from Entocort^® and, 4) unfavorable foreign currency movements of $16 million.

Reported net loss was $70 million, or $0.49 per share versus a net loss of $534 million, or $3.73 per diluted share, in the prior year. Excluding charges as outlined in Table I at the end of this release, second quarter 2017 adjusted net income was $175 million, or $1.22 per diluted share, versus adjusted net income of $185 million, or $1.29 per diluted share, for the same period last year.

Segment Results

 

CHCA second quarter reported net sales were $605 million compared to $630 million last year. Excluding $42 million from VMS in the prior year, adjusted net sales grew 3%. This increase was driven by higher sales in the smoking cessation and dermatologic categories and stronger performance in our Mexico business compared to the prior year. New product sales of $13 million were led by continued strong net sales of the store brand version of Flonase^®, which launched mid-quarter last year. These positive drivers were partially offset by lower sales primarily in the animal health, analgesics and cough and cold categories, along with discontinued products of $3 million.

The CHCA segment achieved second quarter reported gross profit margin of 33.7% and adjusted gross profit margin of 35.7%.  Sell through of higher margin products in the prior year and year-over-year price erosion in certain categories were partially offset by positive contributions from supply chain and manufacturing efficiencies versus last year.

Reported operating margin was 17.2% and adjusted operating margin was 21.0%, which was lower compared to the prior year due to lower gross margin flow through.

 Reported net sales decreased 9% compared to the second quarter of 2016. Net sales grew approximately 4% excluding $39 million from the exited unprofitable European distribution businesses and unfavorable foreign currency movements of $16 million. This increase was driven by new product sales of $19 million and higher net sales in the allergy, analgesic and cough and cold categories.

Second quarter reported gross margin was 46.2%, an increase of 110 bps over the previous year. Adjusted gross margin was 51.7%, an increase of approximately 230 bps over the previous year as the Company exited the unprofitable distribution businesses.

Reported operating margin was 1.0% compared to 0.1% in the previous year. Adjusted operating margin was 14.6%, which included higher advertising and promotional investments as a percentage to net sales compared to the prior year and lower operating expenses as a result of cost improvement initiatives. 

Reported net sales in the second quarter were $240 million, a 13% decrease compared to last year due primarily to lower year-over-year Entocort^® net sales of $26 million and lower sales of other existing products of $14 million, due primarily to price erosion, both of which were consistent with our expectations. Partially offsetting these declines were higher sales volumes of other existing products and new product sales of $6 million.

Adjusted gross margin was 58.8%, 200 bps higher than the prior year as sales of higher margin products and a reduced level of floor stock adjustments compared to the prior year more than offset Entocort^® competition and price erosion.

Reported operating margin was 28.8%. Adjusted operating margin was 46.5%, 370 bps higher than the prior year due primarily to gross margin flow through, the restructuring of the specialty pharma sales force and timing of R&D investments. Adjusted operating income grew by 21%, or $19 million, excluding the effect of Entocort^®.

Guidance

The Company now expects calendar year 2017 reported diluted EPS to be in the range of  $0.84 to $1.09. Given continued positive execution across all of our business segments, the Company raised its calendar year 2017 adjusted diluted EPS guidance to be in the range of $4.45 to $4.70. This adjusted diluted EPS guidance range includes the removal of approximately $0.05 second half expected contribution due to the sale of the API business.

Conference Call

The Company will host a conference call at 8:00 a.m. ET (5:00 a.m. PT), August 10, 2017. The conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 877-248-9413, International 973-582-2737, and reference ID #58567537. A taped replay of the call will be available beginning at approximately 12:00 p.m. (ET) Thursday, August 10, until midnight Sunday, August 20, 2017. To listen to the replay, dial 800-585-8367, International 404-537-3406, and use access code 58567537.

About Perrigo

Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products^®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world's largest manufacturer of over-the-counter ("OTC") healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of "extended topical" prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com).

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and the Company's ability to realize the desired benefits thereof; the Company's ability to achieve its guidance; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives.  In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of any restatement or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2016, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Non-GAAP Measures         

This press release contains certain non-GAAP measures. A "non-GAAP financial measure" is defined as a numerical measure of a company's financial performance that excludes or includes amounts different from the most directly comparable measure calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) in the statements of operations, balance sheets or statements of cash flows of the Company. Pursuant to the requirements of the U.S. Securities and Exchange Commission, the Company has provided reconciliations for net sales on a constant currency basis, net sales excluding sales attributable to held-for-sale businesses, the European distribution businesses, Entocort^® and, adjusted gross profit, adjusted operating income, adjusted net income, adjusted diluted earnings per share, adjusted gross margin, adjusted operating margin, and adjusted diluted shares within this press release to the most directly comparable U.S. GAAP measures for these non-GAAP measures. These non-GAAP financial measures should be considered as supplements to the GAAP reported measures, should not be considered replacements for, or superior to the GAAP measures and may not be comparable to similarly named measures used by other companies.

The Company provides non-GAAP financial measures as additional information that it believes is useful to investors and analysts in evaluating the performance of the Company's ongoing operating trends, facilitating comparability between periods and companies in similar industries and assessing the Company's prospects for future performance. These non-GAAP financial measures exclude items, such as impairment charges, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or that we believe obscure underlying business operational trends. The non-GAAP measures the Company provides are consistent with how management analyzes and assesses the operating performance of the Company, and disclosing them provides investor insight into management's view of the business. Management uses these adjusted financial measures for planning and forecasting in future periods, and evaluating segment and overall operating performance. In addition, management uses certain of the profit measures as factors in determining compensation.

Non-GAAP measures related to profit measurements, which include adjusted gross profit, adjusted operating income, adjusted net income, and adjusted diluted earnings per share, are useful to investors as they provide them with supplemental information to enhance their understanding of the Company's underlying business performance and trends, and enhance the ability of investors and analysts to compare the Company's period-to-period financial results. Management believes that adjusted gross margin and adjusted operating margin are useful to investors, in addition to the reasons discussed above, by allowing them to more easily compare and analyze trends in the Company's peer business group and assisting them in comparing the Company's overall performance to that of its competitors. The Company discloses adjusted net sales, which excludes operating results attributable to held-for-sale businesses, the European distribution businesses and Entocort^® in order to provide information about sales of the Company's continuing business. In addition, the Company discloses net sales growth and adjusted net sales growth on a constant currency basis to provide information about sales of the Company's continuing business excluding the exogenous impact of foreign exchange. The Company believes these supplemental financial measures provide investors with consistency in financial reporting, enabling meaningful comparisons of past, present and future underlying operating results, and also facilitate comparison of the Company's operating performance to the operating performance of its competitors.

A copy of this press release, including the reconciliations, is available on the Company's website at www.perrigo.com.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SOURCE Perrigo Company plc